ESMO Open· @ESMO_Open · X·· 20 小时前评分70
正文 · 机器翻译
HER2+mBC 孤立性 icPD 接受局部治疗后加用 Tucatinib 联合 Trastuzumab/Pertuzumab：@ESMO_Open 的 Ph2 BRIDGET 试验主要结果于 #ESMO2026 公布。中位 icPFS 尚未达到（mFUP 19.6 个月），截至数据截止时，47 例患者中有 46 例存活。https://www.esmoopen.com/article/S2059-7029(26)02587-1/fulltext
19 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1766RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.org来源：ESMO Open · x.com